SuperworthCullinan Therapeutics CGEM
- Market cap
- $924.8M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $33.8M+72% | $34.8M+63% | $30.6M−41% | $36.3M+32% | $35.5M+5% | $40.5M+16% | $41.5M+35% | $61M+68% | $42M+18% | $42.9M+6% | $42.1M+2% | $44.4M−27% |
| SG&A | $11M+9% | $10.6M−6% | $12.3M+16% | $13.8M+35% | $13.3M+22% | $14.6M+37% | $13.5M+10% | $14.8M+7% | $13.6M+2% | $12.3M−15% | $11.6M−15% | $12.8M−13% |
| −$45.2M+52% | −$45.5M+40% | −$43M−32% | −$50M+33% | −$48.9M+8% | −$55M+21% | −$55M+28% | −$75.8M+52% | −$55.6M+14% | −$55.3M+0% | −$53.7M−2% | −$57.3M−25% | |
| Pre-tax income | −$39.2M+43% | −$39.7M+37% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| $0 | −$14.1M+660% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$39.2M+58% | −$23.8M−11% | −$37.1M−36% | −$42M+31% | −$40.6M+4% | −$47.6M+100% | −$48.5M+31% | −$70.1M+67% | −$50.6M+25% | −$50.7M+6% | −$49.7M+2% | −$53.7M−23% |
| −$0.91+69% | −$0.56−5% | −$0.86−39% | −$0.75−9% | −$0.69−24% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| 42.7M−6% | 42.8M−7% | 43M+6% | 55.1M+38% | 58.3M+37% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS, diluted: 4 periods, Q4 FY20 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY20 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Cullinan Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CGEMCullinan Therapeutics | $924.8M | n/m | 5.3× | n/m | n/m | n/m | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | 20.9× | +23% | 54.8% | |
| Peer median | $2.2B | 15.3× | 34.2× | 4.7× | +23% | 23.5% |
More on Cullinan Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .